Medically reviewed by clinical staff at OC Weight Loss and Medspa. Last updated May 2026.
The short version: Wegovy and Mounjaro are not the same drug. Wegovy is semaglutide, a single-target GLP-1 agonist, and it is FDA-approved for chronic weight management. Mounjaro is tirzepatide, a dual GLP-1 and GIP receptor agonist, and it is FDA-approved for type 2 diabetes — the weight-loss-labeled version of tirzepatide is sold as Zepbound. In head-to-head trials of their active ingredients, tirzepatide produced more average weight loss than semaglutide at the highest doses, but both work and the right choice depends on insurance coverage, side-effect tolerance, and whether you have diabetes.
This is the question that comes up in almost every first GLP-1 consultation. The two drugs are talked about together, advertised together, and sometimes prescribed interchangeably — but they are different molecules, FDA-approved for different conditions, and they produce different average results. This guide walks through the science, the trials, the side effects, and the practical decisions: insurance, cost, dose ramp, and what each looks like in real-world use. For a wider view of the medication class, see our GLP-1 weight loss guide, and for the more direct weight-loss-label comparison see our post on Zepbound vs Wegovy.
What is Wegovy?
Wegovy is the brand name for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist made by Novo Nordisk. It is delivered as a once-weekly subcutaneous injection at doses up to 2.4 milligrams. Wegovy was FDA-approved in 2021 specifically for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as hypertension, dyslipidemia, or type 2 diabetes.
The same molecule — semaglutide — is also sold under the brand name Ozempic for type 2 diabetes (maximum dose 2.0 mg) and Rybelsus in oral form. Ozempic is not FDA-approved for weight loss even though it is often prescribed off-label for that purpose.
What is Mounjaro?
Mounjaro is the brand name for tirzepatide, made by Eli Lilly. Tirzepatide is a once-weekly subcutaneous injection that activates two incretin receptors instead of one: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). It is FDA-approved for the treatment of type 2 diabetes, with a maximum dose of 15 mg.
The same active ingredient — tirzepatide — was FDA-approved in 2023 under the brand name Zepbound for chronic weight management. Clinically, Mounjaro and Zepbound are the same drug at the same dose range. The distinction is regulatory: Mounjaro’s label is diabetes, Zepbound’s label is weight management. When patients say “Mounjaro for weight loss,” they are talking about the same molecule that is sold as Zepbound. See our tirzepatide for weight loss post for the full clinical picture.
What is the difference between Wegovy and Mounjaro?
Three differences matter. The drug class. The FDA-approved label. The average results in the pivotal trials.
How do Wegovy and Mounjaro work?
Both drugs mimic naturally produced gut hormones that are released after a meal. These hormones act on the brain, the stomach, and the pancreas — slowing gastric emptying so food stays longer in the stomach, reducing appetite signals from the hypothalamus, and improving insulin response.
Wegovy targets only the GLP-1 receptor. Mounjaro targets GLP-1 and GIP simultaneously. The clinical thinking is that GIP adds two things on top of GLP-1: an effect on how fat tissue handles energy storage, and a modest reduction in the nausea typically seen with GLP-1 agonists. Whether GIP is fully responsible for the larger average weight loss seen with tirzepatide is still debated, but the trial outcomes are consistent with the dual-target hypothesis.
What does the research show?
Two trials anchor the comparison.
- STEP-1 (semaglutide / Wegovy): Adults with obesity and no diabetes lost an average of 14.9% of body weight at 68 weeks on semaglutide 2.4 mg versus 2.4% on placebo (Wilding et al., NEJM 2021, PMID 33567185).
- SURMOUNT-1 (tirzepatide / Mounjaro / Zepbound): Adults with obesity and no diabetes lost an average of 15.0%, 19.5%, or 20.9% of body weight at 72 weeks on tirzepatide 5 mg, 10 mg, or 15 mg respectively, versus 3.1% on placebo (Jastreboff et al., NEJM 2022, PMID 35658024).
SURMOUNT-1 used a slightly longer follow-up (72 vs. 68 weeks) and the populations were similar but not identical, so the head-to-head comparison is indirect. In 2024, Lilly’s SURMOUNT-5 study directly compared tirzepatide to semaglutide in adults with obesity without diabetes; tirzepatide produced about 20.2% average weight loss versus about 13.7% for semaglutide. Reasonable interpretation: tirzepatide at top dose produces more average weight loss than semaglutide at top dose, but both substantially outperform lifestyle alone.
On the cardiovascular side, Wegovy carries an additional label for major adverse cardiovascular event reduction in adults with established cardiovascular disease and overweight or obesity, based on the SELECT trial (Lincoff et al., NEJM 2023, PMID 37952131). Tirzepatide’s cardiovascular outcomes trial (SURPASS-CVOT) is ongoing.
Who is Wegovy or Mounjaro for?
Candidacy depends on two things: medical criteria and insurance criteria, and they often disagree.
- Wegovy (semaglutide): FDA-approved for adults with a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea. Also approved in adolescents aged 12 and older with obesity.
- Mounjaro (tirzepatide): FDA-approved for adults with type 2 diabetes as an adjunct to diet and exercise. If you do not have type 2 diabetes and want tirzepatide for weight loss, the appropriate prescription is Zepbound, which uses the same BMI thresholds as Wegovy.
Contraindications are similar: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, a history of severe hypersensitivity to the drug, and pregnancy. A history of pancreatitis or severe gastroparesis is a strong relative contraindication and warrants a careful conversation with the prescriber. For more on candidacy and labs, see our post on semaglutide vs tirzepatide.
What are the side effects of Wegovy vs Mounjaro?
Side-effect profiles overlap heavily. The dominant complaints with both drugs are gastrointestinal:
- Nausea — most common, usually peaks in the first one to two weeks after a dose increase and improves
- Diarrhea or constipation
- Decreased appetite (this is the intended effect, not always experienced as a side effect)
- Reflux and burping
- Fatigue, especially during dose titration
Less common but more serious risks include pancreatitis, gallbladder events, severe gastrointestinal events, allergic reactions, and acute kidney injury related to dehydration. There is a boxed warning for both medications regarding thyroid C-cell tumors observed in rodent studies; the relevance to humans is unclear but the contraindication for personal or family history of medullary thyroid carcinoma is firm.
In trials, the side-effect burden was numerically similar between the two drugs, though some sub-analyses suggest a slightly lower nausea rate with tirzepatide at comparable weight-loss-producing doses. Individual experience varies enormously. The single biggest predictor of tolerability is the speed of dose escalation, not the molecule itself — slow ramps almost always produce fewer GI complaints.
How are Wegovy and Mounjaro dosed?
Both are once-weekly subcutaneous injections. Both start at a low dose and step up every four weeks to give the GI system time to adapt.
In practice, both schedules are routinely slowed down. If you are tolerating a dose well but losing weight steadily, there is no rule that requires moving up. If GI symptoms are difficult, holding for an extra four weeks before the next step is reasonable. The optimum dose is the lowest one that produces meaningful weight loss with tolerable side effects.
How much do Wegovy and Mounjaro cost?
Sticker prices (U.S., cash, May 2026):
- Wegovy: approximately $1,350 per month at the pharmacy without coverage
- Mounjaro: approximately $1,050 per month at the pharmacy without coverage
Both manufacturers run savings card programs. Lilly’s Mounjaro savings card and Novo Nordisk’s Wegovy savings program can reduce out-of-pocket cost to about $25 per month for commercially insured patients with a covered indication, with somewhat higher caps for uninsured or off-label patients. Coverage rules change frequently — verify with the manufacturer before assuming a price.
Compounded semaglutide and tirzepatide formulations exist and are typically priced between $250 and $500 per month. The supply environment for compounded GLP-1s has shifted multiple times in 2024 and 2025. Our post on compounded tirzepatide vs brand covers the current rules.
Does insurance cover Wegovy or Mounjaro?
Coverage depends on the indication. Mounjaro is more reliably covered when prescribed for type 2 diabetes; many commercial plans cover it routinely if the patient meets the FDA criteria. Wegovy is more variable — some employer plans cover it for obesity, many exclude weight-loss medications entirely.
Medicare does not currently cover obesity medications. Medicare Part D may cover Wegovy for patients with established cardiovascular disease after the SELECT-trial label expansion, depending on plan formulary. Medicaid coverage varies by state. The most reliable way to confirm coverage is to ask the pharmacy to run a test claim with the actual prescription — formulary documents are often out of date.
Wegovy vs Mounjaro: how do you choose?
A short decision framework that mirrors how this conversation usually goes in clinic:
- You have type 2 diabetes: Mounjaro is appropriate and usually well covered. Wegovy is also available and FDA-approved for use in patients with type 2 diabetes if cardiovascular risk reduction is a priority.
- You do not have diabetes, you want maximum average weight loss, cost is not a barrier: Tirzepatide (as Zepbound) has the larger average effect in trials.
- You have established cardiovascular disease: Wegovy carries the FDA cardiovascular-risk-reduction indication based on SELECT.
- Insurance covers one and not the other: Take what is covered. Both work. The difference between drugs is smaller than the difference between getting the medication and not.
- You have a history of severe GI sensitivity: Either drug requires a slow titration. Some clinicians lean toward tirzepatide for marginally lower nausea rates, but the data are not conclusive.
Frequently asked questions
Is Mounjaro stronger than Wegovy?
At top doses in clinical trials, tirzepatide (the active ingredient in Mounjaro) produced more average weight loss than semaglutide (the active ingredient in Wegovy). SURMOUNT-1 reported up to 20.9% at 72 weeks vs STEP-1’s 14.9% at 68 weeks. SURMOUNT-5 directly confirmed a difference. “Stronger” is reasonable shorthand for “larger average effect.”
Can you switch from Wegovy to Mounjaro?
Yes, with prescriber supervision. Switches usually restart at a low dose of the new drug to avoid stacking GI side effects. Switching is most common when weight loss plateaus on one molecule or insurance coverage changes.
Is Mounjaro FDA-approved for weight loss?
No. Mounjaro is FDA-approved for type 2 diabetes. The same active ingredient is FDA-approved for chronic weight management under the name Zepbound. Many patients and clinicians still say “Mounjaro” in conversation; the regulatory and insurance distinction matters when filling the prescription.
Will I regain weight if I stop Wegovy or Mounjaro?
Trial extension data show that a substantial portion of lost weight returns over the year following drug discontinuation for both molecules. Obesity is a chronic condition; the medications work for as long as they are taken. Maintenance dosing — sometimes at a lower dose — is a reasonable strategy and is discussed in our GLP-1 weight loss guide.
Can you take Wegovy or Mounjaro long term?
Both medications are labeled for long-term use in their FDA-approved indications. Extension data through several years are available and the safety profile has remained consistent with the short-term trials. There is no fixed stopping date — the decision is individualized.
What if I do not lose weight on Wegovy or Mounjaro?
In trial data, roughly 10–15% of patients on semaglutide and 5–10% of patients on tirzepatide at top doses did not reach a 5% weight-loss threshold. Non-response is more common when the dose has not yet reached therapeutic range, when injection technique is inconsistent, or when there is significant lipohypertrophy at the injection site. A re-evaluation around the 12 to 16 week mark on a therapeutic dose is the usual checkpoint.
Are compounded Wegovy or Mounjaro alternatives safe?
Compounded semaglutide and tirzepatide are not FDA-approved products. When obtained from a state-licensed compounding pharmacy with appropriate active pharmaceutical ingredient sourcing and oversight, they are an option many patients use, but they sit in a different regulatory category than the branded products. We work with both options and walk patients through the trade-offs in clinic.
Talk to a clinician at OC Weight Loss and Medspa
Wegovy vs Mounjaro is rarely a one-sentence answer. Insurance, comorbidities, side-effect history, and previous attempts all change the recommendation. If you want a clinician’s read on which medication fits your situation, our GLP-1 weight loss program includes a baseline lab workup and a candid conversation about cost and timelines.
Book a free consultation
Book a Free Consultation